NCT01011374

Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion

Impact of Lucentis on Psychological Morbidity in Patients With Macular Edema and Neovascularization Secondary to Retinal Vein Occlusion

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 45 (estimated)
• Sponsor: Retina Associates of Cleveland, Inc · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This is a prospective, single-center, non-randomized clinical study on the impact of intravitreally administered ranibizumab (Lucentis) treatment on vision-related functioning and emotional well-being in subjects with central or branch retinal vein occlusion.

Conditions

• Venous Retinal Branch Occlusion
• Central Retinal Vein Occlusion
• Retinal Vein Occlusion
• Depression

Interventions

Type	Name	Description
DRUG	ranibizumab (Lucentis)	0.5 mg, administered intravitreally every 4 weeks

Timeline

• Start date: 2009-11-01
• Primary completion: 2012-11-01
• Completion: 2013-11-01
• First posted: 2009-11-11
• Last updated: 2011-03-18

Locations

1 site across 1 country: United States